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Abstract
Background Loss of muscle mass worsens many diseases such as cancer and renal failure, contributes to the frailty syn-
drome, and is associated with an increased risk of death. Studies conducted on animal models have revealed the preponderant
role of muscle proteolysis and in particular the activation of the ubiquitin proteasome system (UPS). Studies conducted in
humans remain scarce, especially within renal deficiency. Whether a shared atrophying programme exists independently of
the nature of the disease remains to be established. The aim of this work was to identify common modifications at the
transcriptomic level or the proteomic level in atrophying skeletal muscles from cancer and renal failure patients.
Methods Muscle biopsies were performed during scheduled interventions in early-stage (no treatment and no detectable
muscle loss) lung cancer (LC), chronic haemodialysis (HD), or healthy (CT) patients (n = 7 per group; 86% male; 69.6 ± 11.4,
67.9 ± 8.6, and 70.2 ± 7.9 years P > 0.9 for the CT, LC, and HD groups, respectively). Gene expression of members of the
UPS, autophagy, and apoptotic systems was measured by quantitative real-time PCR. A global analysis of the soluble muscle
proteome was conducted by shotgun proteomics for investigating the processes altered.
Results We found an increased expression of several UPS and autophagy-related enzymes in both LC and HD patients. The
E3 ligases MuRF1 (+56 to 78%, P < 0.01), MAFbx (+68 to 84%, P = 0.02), Hdm2 (+37 to 59%, P = 0.02), and MUSA1/Fbxo30
(+47 to 106%, P = 0.01) and the autophagy-related genes CTPL (+33 to 47%, P = 0.03) and SQSTM1 (+47 to 137%,
P< 0.01) were overexpressed. Mass spectrometry identified>1700 proteins, and principal component analysis revealed three
differential proteomes that matched to the three groups of patients. Orthogonal partial least square discriminant analysis cre-
ated a model, which distinguished the muscles of diseased patients (LC or HD) from those of CT subjects. Proteins that most
contributed to the model were selected. Functional analysis revealed up to 238 proteins belonging to nine metabolic processes
(inflammatory response, proteolysis, cytoskeleton organization, glucose metabolism, muscle contraction, oxidant detoxifica-
tion, energy metabolism, fatty acid metabolism, and extracellular matrix) involved in and/or altered by the atrophying pro-
gramme in both LC and HD patients. This was confirmed by a co-expression network analysis.
Conclusions We were able to identify highly similar modifications of several metabolic pathways in patients exhibiting dis-
eases with different aetiologies (early-stage LC vs. long-term renal failure). This strongly suggests that a common atrophying
programme exists independently of the disease in human.
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Introduction
Loss of muscle mass worsens many diseases (e.g. diabetes,
cancer, heart failure, respiratory failure, renal failure, and
sepsis), which is known as cachexia.1 Cachexia contributes
to the frailty syndrome and is associated with impaired qual-
ity of life and increased risk of death whatever the causal
disease.2
Cachexia is the consequence of profound changes in the
metabolism of skeletal muscle fibres.3–5 The decrease in mus-
cle mass is due to an imbalance in protein synthesis and pro-
teolysis in favour of the latter. Activation of proteolysis
appeared to play a major role in the occurrence of muscle at-
rophy for rapid degradation of myofibrillar proteins in numer-
ous catabolic models. The ubiquitin proteasome system (UPS)
and autophagy are the predominant proteolytic systems in-
volved.6–10 The UPS is crucial for the atrophying process as
it controls both the degradation of contractile proteins and
the repression of protein synthesis.8,9 The UPS targets the
proteins to be degraded by linking covalently a ubiquitin
(Ub) chain to the substrates to be degraded, which enables
the 26S proteasome to recognize and degrade the targets.11
The Ub chain is catalysed, thanks to an enzymatic cascade
(E1, E2, and E3), with E3s that recognize the substrates and
E2s that generally bring the catalytic activity. In rodent
atrophying muscles, several genes (Ub, 26S proteasome sub-
units, E2s, E3s, etc.) are up-regulated in most catabolic situa-
tions including two muscle-specific E3 ligases, muscle atrophy
F-box (MAFbx or atrogin1) and muscle ring finger-1 (MuRF1).
Although data are scarce in humans, MAFbx and MuRF1 up-
regulation was observed in some catabolic conditions.6
The mechanisms involved in the control of muscle mass
during cachexia can be grouped into three categories: nutri-
tion imbalance, mechanical stress, and neuro-hormonal me-
diators. Indeed, a spontaneous reduction of food intake12,13
and a reduction in physical activity14,15 are frequently en-
countered in many cases of cachexia, and starvation or mus-
cle inactivity is sufficient to induce muscle proteolysis and
atrophy.16,17 However, this only partly explains muscle loss
as increased food intake or physical activity is insufficient to
prevent the occurrence of cachexia in the absence of the
treatment of the causal pathology.18 Several experiments
have shed light on the role of hormonal mediator in different
rodent models of cachexia. Indeed, increased levels of proin-
flammatory cytokines (interleukin-1 and interleukin-6 or tu-
mour necrosis factor alpha),19–21 resistance to insulin-like
growth factor-1 and insulin,22,23 or increased myostatin
levels24,25 were often observed. Studies on the mechanisms
of muscle wasting conducted in humans remain rare,
especially during failure, but some abnormalities described
in animal models have been confirmed. For example, in-
creased levels of myostatin have been found in the rectus
abdominis muscles of patients with chronic renal failure.26
However, it still remains to establish whether the modifica-
tions observed are directly linked to the atrophying pro-
gramme or whether they are specific of the disease itself. In
addition, animal models mostly use young growing rodents,
and muscle wasting is generally studied within 1–2 weeks af-
ter catabolic stimuli. This is very different from human dis-
eases where it is generally detected within longer periods
and in adults. Moreover, the physiology of rodents is not
strictly comparable with that of humans. Proteomic studies
coupled with bioinformatics analysis make it possible to de-
tect proteins that potentially interact and are involved in a
common biological process during muscle cachexia. Yet few
have been conducted in human.27
It is thus crucial to identify (i) the cellular processes modi-
fied in human atrophying skeletal muscles and (ii) whether
common proteome modifications characterize muscle atro-
phy independently of the disease in both early and late
stages. In this study, we used muscles from early-stage lung
cancer (LC) or late-stage chronic haemodialysis (HD) patients
for investigating the role of proteolytic systems and for iden-
tifying the metabolic processes modified either at the
transcriptomic level or at the proteomic level.
Material and methods
Population
This study was performed at the University Hospital of
Clermont-Ferrand (France) on muscle biopsies from three
groups of patients: early-stage LC, chronic HD, and healthy
(CT) volunteers. Patients included were over 18 years old,
with either newly diagnosed LC (for whom surgical resection
was programmed by thoracotomy) or end-stage renal failure
treated for at least 6months by HD and necessitating femoral
bypass revascularization. The control group patients required
hip replacement for osteoarthritis. An activation of caspase-3
was noticed in such patients.28 However, Workeneh et al.
performed the biopsies after 1–1.5 h of surgery. As surgery
increases C-reactive protein (CRP), interleukin-6, and protein
degradation per se (overexpression of MuRF1 and
MAFbx),29,30 caspase-3 activity might have been elevated be-
cause of sampling delay. We therefore took the biopsies right
after skin incision and verified that CT patients exhibited nor-
mal CRP level (median value 3 mg/L).
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Exclusion criteria were acute or chronic infections, diabe-
tes mellitus, corticosteroid or hormone therapy, or preg-
nancy. Glomerular filtration rate of LC and CT patients was
estimated by the Chronic Kidney Disease Epidemiology Col-
laboration equation and had to be >90 mL/min/1.73 m2. Pa-
tients in the HD and CT groups did not exhibit active
neoplasia for at least 1 year after muscle biopsy. A
CRP > 10 mg, which was measured in serum using an auto-
mated hospital-based technique (Abbott TDX), was an exclu-
sion criterion for CT patients. All patients gave written
informed consent prior to study entry. The study (DGS-
2008-A00479-46) was approved by the Sud Est VI Research
Ethics Committee and was conform to the standards set by
the Declaration of Helsinki.
Muscles biopsies
Surgical muscle biopsies were taken at the beginning of the
intervention, using a cold scalpel, in the latissimus dorsi (LC
group) or the vastus lateralis (HD and CT groups). Biopsies
were immediately frozen in liquid nitrogen and stored at
80°C.
Quantitative real-time PCR
Using a small fraction (≈100 mg) of the biopsies, total RNA
was extracted as described by Chomczynski and Sacchi.31
mRNA levels of E3 ligases (MuRF1, MAFbx, Nedd4,
Fbxo30/MUSA1, Trim32, Hdm2, Ozz, and E4B), E2 Ub-
conjugating enzymes (UBE2A, UBE2B, UBE2D, UBE2E1,
UBE2G1, UBE2J1, UBE2J2, UBE2L3, UBE2V1, UBE2V2, and
UBE2N), proteasome subunits (PSMA1, PSMA3, PSMB1,
PSMC1, PSMD2, PSMD4, PSMD7, and PSMD13), markers of
apoptosis (Csp3, Csp9, Bax, and Bcl2), autophagy (CTPL and
SQSTM1), and ATF4 pathway (4EBP1, ATF4, and CHOP) were
determined by quantitative real-time PCR (qRT-PCR). Reverse
transcription of total RNA was performed using the
QuantiTect® Reverse Transcription kit (Qiagen®). qPCR was
performed using the FastStart DNA Master SYBR Green I kit
(Roche), according to the manufacturer’s instructions using
a CFX96 thermocycler (Bio-Rad, Hercules, CA, USA). Calcula-
tions were made using the comparative ΔCt method with
YWHAZ, HPRT1, and 36B4 housekeeping genes. List of
primers used is provided in Supporting Information, Table S1.
Protein extraction
A portion (≈400mg) of the muscle biopsies was homogenized
using a Polytron® (Kinematica, Littau-Luzern, Switzerland) in
8mL of lysis buffer [50 mM 3-(N-morpholino)propanesulfonic
acid pH 7.5, 5 mM ethylenediaminetetraacetic acid pH 8.0,
1 mM phenylmethanesulfonyl fluoride, protease inhibitor
cocktail (10 μL/mL of lysis buffer) (Sigma, St Louis, MO,
USA), N-ethylmaleimide 10 mM, and Triton X100 1%]. Muscle
homogenates were centrifuged at 16 000 g (4°C, 10min), and
the supernatant containing the cytoplasmic fraction was
aliquoted and frozen at 80°C until use. Protein concentra-
tion was measured by absorption spectrophotometry (OD
562 nm) using the BCA kit (Pierce, Rockford, IL, USA) with bo-
vine serum albumin as a standard.
Sodium dodecyl sulfate–polyacrylamide gel
electrophoresis loading and nano-liquid
chromatography–tandem mass spectrometry
analysis of proteins
After reduction and alkylation, 50 μg of proteins were loaded
on a 12% acrylamide sodium dodecyl sulfate–polyacrylamide
gel electrophoresis gel. Proteins were visualized by
Coomassie Blue staining. Each band was cut into a single slice
that was washed in 100 mM ammonium bicarbonate for
15min, followed by a second wash in 100mM ammonium bi-
carbonate:acetonitrile (1:1) for 15 min. Both washes were
performed at 37°C. Second cycle of washes in ammonium bi-
carbonate and ammonium bicarbonate/acetonitrile was then
performed. Proteins were digested by incubating each gel
slice with 1 μg of modified sequencing grade trypsin in
50 mM ammonium bicarbonate overnight at 37°C. The
resulting peptides were extracted from the gel in three steps:
a first incubation in 50 mM ammonium bicarbonate for
15 min at 37°C and two incubations in 10% formic acid:aceto-
nitrile (1:1) for 15 min at 37°C. The three collected extracts
were pooled with the initial digestion supernatant, dried in
a SpeedVac, and resuspended with 50 μL of 5% acetonitrile
and 0.05% trifluoroacetic acid. The peptides were analysed
by nano-liquid chromatography–tandem mass spectrometry
(MS/MS) using an UltiMate 3000 RSLCnano system (Dionex,
Amsterdam, The Netherlands) coupled to an OrbiTrap Fusion
mass spectrometer (Thermo Scientific, Bremen, Germany).
Five microliters of each sample was loaded onto a C18 pre-
column (300 μm id, 5 mm; Dionex), at 20 μL/min, in 5% ace-
tonitrile and 0.05 W% trifluoroacetic acid. After 5 min of
desalting, the pre-column was switched on line with the ana-
lytical C18 column (75 μm id × 15 cm C18 column; packed in-
house with ReproSil-Pur C18-AQ 3 μm resin, Dr Maisch;
Proxeon Biosystems), equilibrated in 95% solvent A (5% ace-
tonitrile and 0.2% formic acid) and 5% solvent B (80% aceto-
nitrile and 0.2% formic acid). Peptides were eluted using a 5–
50% gradient of solvent B over 130 min and at a flow rate of
300 nL/min.
The OrbiTrap Fusion was operated in Data Dependent Ac-
quisition mode to automatically switch between full scan
MS and MS/MS acquisition using Xcalibur software. Survey
scan MS was acquired in the Orbitrap over the m/z 300–
2000 range, with the resolution set to a value of 120 000
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(m/z 400). The most intense ions per survey scan were se-
lected for higher-energy collisional dissociation fragmentation
(time between Master scans: 3 s), and the resulting frag-
ments were analysed in the linear ion trap. Dynamic exclusion
was employed within 60 s to prevent repetitive selection of
the same peptide.
Bioinformatics analysis of mass spectrometry raw
files
Mass spectrometry raw files were analysed using the Proline
software version 1.6. MS/MS spectra were searched in the
Mascot search engine against the forward and reverse Human
SwissProt database combined with a commonly observed
contaminants list. The digestion enzyme was set to
trypsin/with up to two missed cleavages. Methionine oxidation
and N-terminal acetylation were searched as variable modifica-
tions and carbamidomethyl of cysteine as fixed modification.
Parent peptide masses and fragment masses were searched
withmaximal mass deviation of 10 ppm. A first level of false dis-
covery rate (FDR) filtration was done on the peptide-spectrum
match level, and this was followed by a second level of FDR
control on the protein level. Both filtrations were performed
at a 1% FDR. These filtrations were done using a standard
target-decoy database approach. For label-free relative quanti-
fication of the samples, the “match between runs” option of
Proline was enabled to allow cross-assignment of MS features
detected in the different runs. The minimal ratio count was
set to 1 for calculation of abundances, which were used for
relative quantification of proteins between the 3 groups of
samples (CT, HD and LC). Missing data were implemented using
the Imp4p-package (CRAN) working in Prostar.
Statistical analysis
Statistical analysis was performed with XLSTAT v2018.1 soft-
ware (Addinsoft®). The tests were two sided, with a Type I error
set at α = 0.05. Variables were presented as mean ± standard
deviation or median [interquartile range] according to statisti-
cal distribution (assumption of normality assessed by the
Shapiro–Wilk test). For demographic data and qRT-PCR results,
a one-way analysis of variance (ANOVA) was used to compare
values within the three groups, followed by post hoc Tukey test
for pairwise comparison. For MS results analysis, a two-way
ANOVA (group and replicate) was used to compare values in
the three groups followed by Benjamini–Hochberg (BH) correc-
tion. Principal component analysis (PCA) was implemented on
differentially expressed proteins. To focus on the proteins
whose expression best characterized atrophying muscles inde-
pendently of the disease (HD or LC vs. CT), we performed or-
thogonal partial least square discriminant analysis (O-PLS-DA).
Proteins were classified according to their variable importance
in projection (VIP). A VIP > 1 was considered for selecting the
proteins.32 Proteins whose VIP was above 1 and significantly
increased or decreased in both LC and HD patients were then
evaluated using unsupervised hierarchical clustering (k-means
classification and hierarchical ascending classification centred
on Euclidean distances).
Bioinformatic analysis of protein expression data
Bioinformatic analysis was performed using Cytoscape soft-
ware v3.6.0.33 Proteins whose VIP was above 1 and concomi-
tantly increased or decreased in LC and HD patients when
compared with CT patient were considered as common
markers of muscle atrophy process. Identification of the func-
tions of these proteins was implemented with ClueGO
v2.5.0.34 A network of Gene Ontology biological process was
created allowing to group the redundant term in functional
cluster. Enrichment analysis was then performed for each
cluster. GO levels 5 to 15were considered. The kappa-statistics
score threshold to create edge between nodes was set to 0.56.
A two-sided (enrichment/depletion) hypergeometric test
followed by BH correction was used to perform enrichment
analysis. Group fusion option was used to diminish the
redundancy of the terms shared by similar associated proteins,
which allows to maintain the most representative parent or
child GO term. Then, a gene network analysis was implemented
with CluePedia v1.5.035 using the String protein interaction
database (January 2018) in order to identify potential activated
or repressed pathways. In order to validate our results, a pro-
tein co-expression network was created based on the Spear-
man rank correlation at a threshold of 0.6. Then, clustering
was made using ClusterOne.36 Finally, for each cluster, identifi-
cation of the most enriched functions/pathways was per-
formed using GeneMANIA v3.4.1 and default settings.37
Results
Patients’ demographic
Demographic characteristics of the 21 patients included in this
study (n = 7 per group) are shown in Table 1. The three groups
differed neither in age nor in sex ratio with a majority of men
included. The body mass index of patients in the LC and HD
groups was not significantly different compared with patients
in the CT group, and it remained within the normal range.
Systemic inflammation assessed by the CRP measurement
was normal in the CT group (3.0mg/L) for 70 years old patients
and was significantly higher (more than three-fold to four-fold)
in the LC and HD patients. Glomerular filtration rate estimated
by the Chronic Kidney Disease Epidemiology Collaboration
equation was similar in the CT and LC groups and within the
normal range considering the age of the patients.
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The ubiquitin proteasome system and autophagy
proteolytic system are activated in the muscle of
lung cancer and haemodialysis patients
Studies conducted on cells or animal models have identified
several genes whose expression is modified during muscle
atrophy. These genes, called atrogenes, are markers of mus-
cle wasting. Notably, they belong to cellular proteolytic sys-
tems such as the UPS and autophagy. In order to address
the activation of atrophy in LC and HD patients, qRT-PCR
was performed to quantify in muscles biopsies the expres-
sion of several genes belonging to several proteolytic sys-
tems. Atrogenes include several E3 ligases of the UPS,
which are often good markers of atrophy. We thus ad-
dressed different E3 ligases that have been described for
their implication in muscle homeostasis. MuRF1, MAFbx,
Hdm2, and Fbxo30/MUSA1 E3 ligases were up-regulated at
the mRNA levels in the muscle of LC and HD patients when
compared with the CT group (Figure 1(A)). In contrast,
Nedd4, E4b, and Trim32 transcripts were only up-regulated
in patients from the HD group, while no variation was ob-
served for Ozz (Figure 1(A)). E3 ligases work in couple with
E2 Ub-conjugating enzymes to ensure the ubiquitination of
their substrate. We therefore quantified the expression of
several E2s already described for being up-regulated in sev-
eral catabolic situations in rodents (Figure 1(B)). However,
only UBE2E1 and UBE2V2 transcripts were increased in LC
patients and UBE2A and UBE2J1 in HD patients. We then ad-
dressed 26S proteasome subunits, but surprisingly, no signif-
icant variation was found for the 20S complex subunits
(Figure 1(C)). For the 19S regulatory complex (19S RC), only
an increase in PSMD13 mRNA levels was found in both LC
and HD patients, while PSMD2 and PSMD4 were up-
regulated only in HD patients (Figure 1(D)). We selected
CTPL and p62/SQSTM1 as markers of the autophagy proteo-
lytic system. Increased mRNA levels of both CTPL and
p62/SQSTM1 were found in both LC and HD patients (Figure
1(E)), suggesting that autophagy was activated. Muscle atro-
phy may also be accompanied by apoptosis of muscle cells.
Indeed, we found increased levels of the pro-apoptotic
Casp3, Casp9, and Bax transcripts and a decrease of the
anti-apoptotic Bcl2, but the modifications were restricted
to HD patients (Figure 1(F)). Altogether, our data suggest
an up-regulation of the UPS and the autophagy proteolytic
systems, the most sensitive markers of the UPS being E3 li-
gases, that is, enzymes that select the proteins to be
degraded.
A specific proteome identifies atrophying muscle
independently of the aetiology of the disease
As we found an increased transcription of atrophying genes in
muscles from LC and HD patients, we then addressed poten-
tial changes in the muscle proteome. MS analysis of the cyto-
plasmic fraction identified 1779 proteins (Supporting
Information, Table S2), of which 919 were differently
expressed in at least one group (P < 0.05 ANOVA for group
factor after BH correction). Out of them, 257 proteins were
increased or decreased in both LC and HD patients when
compared with CT patients (Figure 2(A)). Moreover, LC/CT
and HD/CT expression ratios of these proteins were well cor-
related, indicating that their variation levels were highly sim-
ilar independently of the disease (Figure 2(B)).
Principal component analysis was performed on proteins
differently expressed between the three groups (Figure
3(A)). PCA allows reducing the number of correlated variables
to a limited number of independent variables (principal com-
ponents) that better explain the observed variance. PCA
grouped the proteins into three distinct sectors of the space
generated by the two principal components, which nicely
fitted respectively to the CT, LC, and HD groups (Figure
3(A)). This indicates that each patient’s group exhibited a spe-
cific proteome and that a distinct signature can be drawn for
CT, LC, and HD patients.
We then decided to focus on proteins that best character-
ized atrophying muscles independently of the causal pathol-
ogy, and we performed an O-PLS-DA (Figure 3(B)). The
horizontal component of the O-PLS-DA score scatter plot cap-
tures variation between the groups (LC or HD vs. CT), and the
Table 1 Demographic characteristics of the patients
Control patients (n = 7) Lung cancer patients (n = 7) Haemodialysis patients (n = 7) P
Age (years) 71 [60–79] 69 [62–75] 69 [66–77] >0.9
M:F 6:1 6:1 6:1 >0.9
Weight (kg) 76 [73–78]a 66 [62–72]ab 64 [59–66]b 0.05
Height (cm) 170 [174–182]a 173 [169–176]ab 165 [160–170]b 0.03
BMI 24.8 [23.5–25.1] 21.3 [20.2–24.1] 23.4 [22.4–24.4] 0.15
CRP (mg/L) 3.0 [3.0–7.4]a 9.7 [4.1–37.3]b 12.8 [4.4–22.5]b 0.03
Creatinine (μmol/L) 66 [59–81]a 82 [64–90]a 535 [494–752]b <0.001
GFR (mL/min/1.73 m2) 88 [85–95] 84 [74–94] NA >0.9
BMI, body mass index; CRP, C-reactive protein; GFR, glomerular filtration rate; M:F, sex ratio male-to-female; P-value obtained with one-
analysis of variance.
Values are median and interquartile range.
Values with different letters are significantly different using Tukey multiple comparison post hoc test.
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vertical component captures variation within the groups.
The model obtained exhibited an R2 (measure of model fit
to the original data) of 0.993 and a Q2 (internal measure
of consistency between the original and cross-validation pre-
dicted data) of 0.983. The contribution of proteins to the
model was evaluated by the calculation of the VIP. We
found 321 proteins exhibiting a VIP > 1, which was consid-
ered the threshold for selecting the proteins32 (Figure
3(C)). By crossing these data (321 proteins with a VIP > 1)
with those of the differential expression analysis (257 pro-
teins that both increased or decreased in the LC and HD
groups), we finally selected 238 proteins (Supporting Infor-
mation, Table S3). Using an unsupervised hierarchical cluster
analysis, we then addressed the capacity of these proteins
for discriminating patients according to their original groups
(Figure 3(D)). We found that a majority of proteins were po-
tent indicators of catabolic conditions independently of the
disease.
Figure 1 Quantitative real-time PCR of genes from ubiquitin proteasome system and autophagy proteolytic system. mRNA levels of several compo-
nents from ubiquitin proteasome system and autophagy proteolytic system are increased in muscle of LC and HD patients. P-value obtained with
one-way analysis of variance. Values with different letters are significantly different using Tukey multiple comparison post hoc test. CT, healthy; HD,
haemodialysis; LC, lung cancer.
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Figure 2 Shotgun proteomic analysis of muscle soluble proteome. (A) Volcano plots show differentially expressed proteins based on fold change vs. P-
value obtained with analysis of variance after Benjamini–Hochberg correction. Proteins represented with red point are significantly (P < 0.05) in-
creased or decreased in the muscles from both LC and HD patients. (B) Fold change in protein expression in LC vs. HD patients relative to CT patients.
Change in expression of commonly variant proteins was similar in LC and HD. CT, healthy; HD, haemodialysis; LC, lung cancer.
Figure 3 Multidimensional analysis of differentially expressed proteins in LC and HD groups. Each point represents one of the three patient replicates.
(A) Principal components analysis reveals three different muscle soluble proteomes corresponding to the three different patients groups. (B) Based on
differentially expressed proteins, O-PLS-DA creates a model allowing differentiating muscle of LC and HD patients from muscle of CT patients. (C) 321
proteins with VIP > 1 contribute significantly to the model. (D) For these 321 proteins, unsupervised hierarchical clustering identifies two different
patterns of expression: proteins increased and proteins decreased in both LC and HD patients relative to CT patients. CT, healthy; HD, haemodialysis;
LC, lung cancer; O-PLS-DA, orthogonal partial least square discriminant analysis; PCA, principal component analysis; VIP, variable importance in
projection.
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Biological processes modified upon muscle atrophy
We carried out a functional analysis of the 238 proteins that
best witnessed muscle atrophy using the ClueGO plug-in. This
revealed that these proteins can be grouped in functional
modules related to biological processes significantly enriched
when compared with the healthy human proteome (Figure
4(A) and 4(B)). Overall, it included several metabolic path-
ways (proteostasis, glucose catabolic process, fatty acid, and
energy metabolism), inflammation, defence against free oxy-
gen radicals, structural proteins (cytoskeleton organization
and extracellular matrix protein), and proteins involved in
muscle contractile function (Table 2). Regarding proteolysis,
we found an increase of several proteins related to the UPS
and the autophagy proteolytic systems (Figure 4(C)). To con-
firm these results, we used a different approach. A co-
expression network was created from the 1759 proteins iden-
tified in MS. It was a scale-free network with a node degree
distribution following a power law (R2 = 0.93), confirming its
biological relevance (Figure 5). Using the ClusterOne
algorithm, proteins have been grouped into 50 clusters of
co-expression. Eight cluster displayed enriched functions (cel-
lular respiration, inflammatory response, leucocyte migra-
tion, translation factor activity, muscle contraction,
extracellular matrix, glucose metabolic process, and protea-
some pathway) (Table 3).
The Wnt-β-catenin and ATF4 signalling pathways
are up-regulated in both haemodialysis and lung
cancer patients
In order to identify signalling pathways potentially involved, a
protein interaction network analysis was performed using
CluePedia software. Ten proteins characterizing pathological
muscles belonged to the Wnt-β-catenin pathway, which sug-
gested an activation of this signalling pathway (Figure 6(A)).
Similarly, ERp44 an endoplasmic reticulum (ER) stress marker
was significantly increased in atrophying muscles, and we
thus checked whether the ATF4 pathway was activated in
the patients’ muscles. We found a significant increase of
ATF4, CHOP, and 4EBP1 transcripts in both LC and HD pa-
tients when compared with CT patients (Figure 6(B)).
Discussion
In this study, we focused on skeletal muscle proteolysis and
proteome modifications induced by two diseases (LC and
HD) with a different aetiology and known to induce muscle
atrophy in humans. We first found that the UPS and the au-
tophagy proteolytic systems were concomitantly activated
in both LC and HD patients and that some E3 ligases are
Figure 4 Functional enrichment analysis. (A) Proteins whose expression characterize pathological muscle from lung cancer and haemodialysis patients
are involved in proteolysis, protein folding, amino acid metabolism, glucose catabolic process, fatty acid metabolic process, oxidative phosphorylation,
regulation of inflammatory response, leucocyte migration, cellular oxidant detoxification, regulation of cytoskeleton organization, extracellular matrix,
and striated muscle contraction. (B) Most proteins belong to the inflammatory response and proteostasis processes. (C) Proteins involved in proteolysis
and modified in both lung cancer and haemodialysis patients belong to the ubiquitin proteasome system and autophagy proteolytic system.
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potent markers of human muscle atrophy. We then found a
panel of 238 proteins belonging to nine main cellular func-
tions that characterized atrophying muscles independently
of the disease. Finally, we found that the Wnt-β-catenin and
ATF4 signalling pathways were activated in both HD and LC
muscles. This study was conducted with a limited number
of patients, and the differential proteins (and mRNAs) will
have to be confirmed using larger cohorts of patients, by fo-
cusing on the most variable markers.
In various models of rodent muscle atrophy, several genes
are systematically overexpressed at the transcriptional level,
and these atrophy-related genes (atrogenes) include mem-
bers of the main proteolytic systems (UPS and autophagy).6,38
Regarding the UPS, atrogenes include Ub, 20S proteasome
subunits, 19S regulatory complex subunits, and ubiquitinating
enzymes (E2s and E3s). Indeed, both substrate targeting
(ubiquitination) and degradation (26S proteasome) steps are
up-regulated in various catabolic situations (fasting, diabetes
mellitus, renal failure, tumour bearing, and hindlimb suspen-
sion).17,39,40 Surprisingly, in this study, proteasome subunits
(belonging either to the 20S proteasome core or to the 19S
regulatory complex) appeared to be poor predictors of the
atrophying process in humans. Indeed, none of the 20S and
19S RC subunits tested were up-regulated in both LC and
HD patients at the mRNA levels, and only three of them were
increased at the protein levels (Figure 1(C) and 1(D), Table 2,
and Supporting Information, Table S1). E2 enzymes appeared
also to be poor predictors of muscle atrophy in LC and HD pa-
tients (Figure 1(B) and Supporting Information, Table S1) in
contrast with animal models in which UBE2B was considered
as a bona fide atrogene and other E2s were often up-
regulated during catabolic situations (see Polge et al.41 for
compiled data).
Several E3 ligases were up-regulated in both LC and HD pa-
tients and more particularly MuRF1 and MAFbx, two muscle-
specific E3 ligases considered as the best markers of muscle
Table 2 Enriched biological process in LC and HD patients
Increased expression Decreased expression Enrichment P-value
Proteostasis
Proteolysis
CAPNS1, CTTNB, CUL1, CUL2, I,
PSMA3, PSMB1, PSMD13, GAPDH,,
NPEPPS, QDPR, SCFD1, PGEP1,
SERPINB1, SERPINB6, UBE2I, USP9X
APCS, ASPN, AZU1, BGN, CASP14,
CLU, PARK7, PIP, SERPINB3, UBE3A,
USP13, UCHL5
2,6E7
Protein folding
BOLA2, GNB1, CLU, APCS, HSPA6,
B2M, ERP44, PPIH, TXNDC5,
HSPA1B PARK7, STT3B
AHSA1, HSPE1 1.7E3
Cellular amino
acid metabolic
process
AARS, AIMP1, BCKDK ADI1, DBT, DDAH2, 5E3
Glucose catabolic process AKR1B1, ENO2, ENO3, GAPDH, GPD1,
PFKFB1, PFKFB2, PGAM1, PGAM2, PGK1,
PGLS, PGM1, PHKA1, PHKG1, PGPEP1,
PKM, PTBP1, LDHD, UGP2,
SORD 2.5E7
Fatty acid metabolism ACAD9, AKR1C2, ECHDC2, FTO,
HSD17B12, GPD, PLIN2, ZADH2
ACAA1, CDS2 1,4E4
Energy metabolism
Acetyl Co A biosynthetic
process
ACSS1, LDHD MPC1 5.2E4
Oxidative phosphorylation NDUFA1, MRP44, MIC13 ATP5D, DMAC1, SARS2, USP13, VGF 5E3
Inflammatory response
Regulation of defence
response
ABCE1, AIMP1, ARPC1A, B2M, CUL1,
F13A1, FGA, FGB, FGG, GAPDH, GRB2,
IGHD, HSP1A, LTA4H, NLRX1, PSMA3,
PSMB1, PSMD13, PTGIS, SAMHD1,
SERPINB1, STAT3, SCNA
APCS, AZU1, BPI C4B, C5, MPO, PRTN3,
CD47, CFHR2, KRT1, LCN2, LGAL3,
NOS2, PARK7, PCBP2, PROS1, SAA,
S100A7, S100A8, S100A9
3.3E7
Leucocyte migration
AIMP1, BOLA2, CD47, GRB2, IGKV4–1,
PRTN3, RHOA, STAT3
ADD2, AZU1, C5, CLU, GYPA, IGLV1–47,
LCP1, LGALS3, MPP1, PROS1, SAA1,
S100A7, S100A8, S100A9
1,8E5
Extracellular matrix FBLN5, GMPPB, PEPD, SERPB1 APCS, ASPN, BGL, CILP, FMOD, PIP 3.4E02
Skeletal muscle contraction CFL2, CSRP3, KELCCH, KLHL41, MYL4,
MYH15, MYPN, ANXA6, ATP1A2,
GPD1-L, NIPSNAP2
MYH6, NRAP, PLN, SLC20A2 8,5E4
Cytoskeleton organization ACTBL2, ARHGDIA, ARPC1A, CFL2,
CTNNB1, GDI1, NUBP2, PFN2, PRUNE1,
RHOA, SNCA
ADD2, DMTN, FLNA, JUP, KRT1, KRT2,
LCP1, MYOC, PALM, S100A8, S100A9,
TUBA1A, TUBB1
1.3E4
Cellular oxidant detoxification AKR1B1, CCS, FAM213A, FBLN5,
GSTM2, GSTT1, MPO, NUP93, NQO1,
PARK7, S100A9, TXNRD, HAGH
9.9E6
Enriched biological process have been identified from the 321 proteins whose expression was significantly increased or decreased in both
lung cancer (LC) and haemodialysis (HD) patients, using ClueGO® plug-in in Cytoscape®.
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atrophy in rodents.6,42 Even though human studies are rela-
tively scarce compared with rodent, several investigations
also observed an up-regulation of MuRF1 and MAFbx follow-
ing immobilization, spinal cord injury, or chronic obstructive
pulmonary disease.6 The sustained up-regulation of these
E3 ligases over years (HD patients) suggests that both an in-
creased degradation of the contractile apparatus (i.e. MuRF1
targets like α-actin, myosin heavy chains, and telethonin) and
a repression of protein synthesis and anabolic factors (i.e.
MAFbx targets like eIF3f and MyoD) are necessary for main-
taining long-term muscle atrophy.7–9,41,43 In our study, we
also found that two other E3 ligases were up-regulated at
the mRNA level, that is, human double minute (Hdm2) and
F-box protein 30/muscle Ub ligase of the SCF complex in
atrophy-1 (Fbxo30/MUSA1). Hdm2 is a ubiquitous E3 ligase
mostly known for its role in p53 ubiquitination during cancer
development, but it is also up-regulated in muscles from
hindlimb suspended rats, a model of hypokinesia.17 Finally,
Fbxo30/MUSA1 is a muscle-specific E3 ligase that was de-
scribed as essential for the development of muscle atrophy
in several rodent models with the exception of mild renal fail-
ure in rats, but Fbxo30/MUSA1 targets remain to be discov-
ered.10,42,44–46 The recruitment of E3 ligases in catabolic
patients was further demonstrated at the proteome level.
Figure 5 Proteins co-expression network analysis. Spearman rank correlation for expression of all possible protein pair is calculated. In graph, proteins
are represented with nodes, and an edge is created between two nodes if the Spearman rank correlation for the expression of the two proteins among
all patients is above 0.6. Node degree distribution followed a power law. The ClusterOne algorithm led to the identification of 50 clusters of co-
expressed proteins.
Table 3 Functions of clusters of expression
Cluster Enriched function Q-value Proteins involved
1 Cellular respiration 1.0E161 ACO2, ALDH5A1, ATP5A1, ATP5B, ATP5C1, ATP5D, ATP5F1, ATP5H, ATP5I, ATP5J2,
ATP5L, ATP5O, COX4I1, COX5A, COX5B, COX6B1, COX6C, CS, CYC1, CYCS, DLD, DLST,
ETFA, ETFB, ETFDH, FH, IDH2, IDH3A, IDH3G, MDH2, MT-ATP6, MT-CO2, NDUFA10,
NDUFA11, NDUFA12, NDUFA13, NDUFA2, NDUFA4, NDUFA5, NDUFA6, NDUFA8,
NDUFA9, NDUFAB1, NDUFB1, NDUFB10, NDUFB11, NDUFB3, NDUFB4, NDUFB5,
NDUFB6, NDUFB7, NDUFB8, NDUFB9, NDUFC2, NDUFS1, NDUFS2, NDUFS3, NDUFS4,
NDUFS6, NDUFS7, NDUFS8, NDUFV1, NDUFV2, NNT, OGDH, PDHA1, PDHB, SDHA, SDHB,
SLC25A12, SLC25A13, SUCLA2, SUCLG1, UQCRB, UQCRC1, UQCRC2, UQCRFS1, UQCRH
2 Inflammatory response 7.9E18 A2M, AGT, AHSG, APOA1, APOD, APOE, C3, C4A, C9, CFB, CFH, ITIH4, KNG1, ORM1,
SERPINA3, SERPING1, VTN
3 Leucocyte migration 2.3E06 AZU1, CD47, ITGB3, MPP1, PROS1, S100A7, S100A8, SAA1
4 Translation factor
activity
4.5E10 EEF1A2, EIF2S1, EIF3E, EIF3I, EIF4A2, EIF4G1
5 Muscle contraction 1.1E58 TPM1, TMOD4, TNNT3, MYL1, TNNI2, TPM2, MYH7, MYH2, TPM3, ACTN3, TMOD1,
MYL3, ASPH, MYL6B, TNNI1, MYL5, MYH3, ACTN2, TNNT1, TNNC1, ACTA1, MYBPC2,
MYL2, MYH4
6 Extracellular matrix 4.4E5 COL15A1, CILP, SNCA, FMOD
7 Glucose metabolic process 2.6E36 PGK1, PGAM2, ALDOA, ENO2, PGM1, FBP2, GAPDH, ENO3, GPI, ALDOC, TPI1
8 Proteasome complex 1.1E71 PSMA5, PSMA3, PSMD6, PSMD4, VCP, PSMA1, PSMB7, PSMB1, PSMA7, PSMB2
Eight clusters of expression identified using ClusterOne® display enriched function in GeneMania®.
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Indeed, we found that the Cul1 and Cul2 were up-regulated
in both LC and HD patients (Table 2 and Supporting Infor-
mation, Table S3). Cul1 and Cul2 are scaffold proteins in-
cluded in several multi-subunits Cullin-Ring E3 ligases,
which means that numerous E3 ligases belonging to this
family may be up-regulated in LC and HD patients. Interest-
ingly, Cul1 is the Cullin integrated to the multi-subunits
MAFbx E3 ligase, which corroborates the data obtained at
the mRNA level. Altogether, we found that several compo-
nents of the UPS were up-regulated in both LC and HD pa-
tients (Figure 1, Table 2, and Supporting Information, Table
S3) but this was restricted to E3 ligases, which is in striking
contrast with rodent models. The main difference between
animal models and human pathologies is the timing, which
is generally in days for animal models while it is in months
or years for humans. Indeed, even though we recruited LC
patients soon after cancer discovery, the atrophying process
was probably already activated for weeks. However, body
mass index was within the normal range, which suggests
that LC and HD patients were not severely cachectic. We hy-
pothesize that the 26S proteasome and the E2 enzymes do
not need to be maintained up-regulated once the pathology
is established, the enzyme activity being sufficient for main-
taining the skeletal muscle in a catabolic state. In contrast,
some E3 ligases (MuRF1, MAFbx, Hdm2, and
Fbxo30/MUSA1) are involved in the atrophying programme
in both very early (3–7 days, rodents) and late (>1 year,
humans) stages of muscle atrophy.
Figure 6 Signalling pathways activated in lung cancer (LC) and haemodialysis (HD) patients. (A) Analysis based on String protein interaction database
predicts that the Wnt pathway signalling is activated in LC and HD patients. (B) Increased mRNA levels of ATF4, CHOP, and 4EBP1 revealed activation of
the ATF4 pathway in both LC and HD patients.
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Autophagy is known for playing a crucial role in atrophying
muscles from rodents,10,47,48 and we found that p62/SQSTM1
was up-regulated in LC and HD patients. p62 is a cargo recog-
nition protein implicated in the selective addressing of pro-
teins (or protein aggregates) or organelles to the autophagy
machinery. Increased p62 transcription levels are thus di-
rectly linked to an increased autophagy flux. We also found
that cathepsin L (CTPL) and myosin heavy chain 15 (MYH15)
were also up-regulated in both LC and HD patients. CTPL is
a lysosomal protease (the catalytic organelle of autophagy)
and is also known to be an atrogene in rodent muscles.17,40
MYH15 is a heavy chain of myosin involved in the transport
of lysosomal vesicles. Our data are in accordance with previ-
ous studies demonstrating that LC3B (a protein crucial for
autophagosome formation) and CTPL were up-regulated in
muscles from cancer cachexia patients.49 Similarly, autophagy
was activated in nephrectomized mice, causing mitochondria
dysfunction without affecting the contractile apparatus.50 Al-
together, key proteins of autophagy were up-regulated in
both LC and HD patients, which represent potent and persis-
tent markers of muscle atrophy.
Another main goal of our study was to find a shared
atrophying pattern in patients developing diseases with a
completely different aetiology and at different stages. Our
hypothesis was that similar protein modifications in LC and
HD patients are more likely due to the atrophying process
rather than the pathology itself. Interestingly, we found 238
proteins that were either down-regulated or up-regulated in
both LC and HD patients. Interestingly, numerous proteins
of unknown function (at least in skeletal muscle) were among
the ones undergoing the sharpest modifications. For exam-
ple, several proteins positively correlating with cellular prolif-
eration were down-regulated, such as dermcidin (76 to
80%, P < 1.0E07). Future studies will have to investigate
the role of these proteins in the development of muscle atro-
phy, but one hypothesis is that a sustained repression of cell
proliferation may be an adaptive mechanism of muscle
atrophy.
Besides proteins of unknown functions, our data
highlighted an activation of ER stress in both LC and HD pa-
tients. We found that several chaperones were up-regulated
in the skeletal muscle of these patients, notably ERp44 a
marker of ER stress (+234 to +368%, P < 1.0E29). ERp44
is a pH-regulated chaperone of the secretory pathway, which
controls oxidative-related protein misfolding in the ER.51
These results are in accordance with studies showing that
ER stress is activated in several catabolic situations (denerva-
tion, starvation, high-fat diet, cancer cachexia, and ageing).52
The ER stress response can be activated by several stress fac-
tors (nutrient deprivation, reactive oxygen species, etc.) and
more recently in mice injected with indoxyl sulfate, a uraemic
toxin.53 However, it is the first time that an ER stress is de-
tected in HD patients. The ER stress response involves in par-
ticular the PERK/ATF4/CHOP signalling pathway that
decreases overall protein translation, triggers the specific ex-
pression of chaperones, activates the UPS and autophagy
proteolytic systems, and may ultimately lead to apoptosis.54
Accordingly, we found an up-regulation of CHOP, ATF4, and
4EBP1 (a downstream key protein of this pathway) in the
muscles from both LC and HD patients (Figure 6(B)).
Another striking effect of both cancer and renal failure was
the increased expression of several glycolytic enzymes and
the down-regulation of several proteins involved in mito-
chondrial respiration in the muscle from LC and HD patients
(Tables 2 and 3). This is in agreement with the slow oxidative
to fast glycolytic transformation process observed during
muscle atrophy55 and the increased expression of several gly-
colytic enzymes observed in atrophying muscles from
hindlimb suspended,56 denervated,57 or immobilized58 ani-
mals. Mitochondrial dysfunction has also been found in dif-
ferent rodent models of cachexia50,59 and is a regulator of
myofiber protein turnover and apoptosis.60 The proposed
model is that mitochondrial dysfunction may precede the in-
stallation of muscular atrophy.61 Increased reactive oxygen
species62 and inflammation63 have also been proposed to ex-
plain the metabolic changes associated with muscle atrophy.
Future studies will have to clarify the role of the modifications
in the occurrence of muscle wasting.
Muscle atrophy is accompanied by modifications of pro-
teins involved in contraction and in the architecture of muscle
tissue, including cytoskeleton,64 increased muscle fibrosis,65
and adipogenic infiltration.66 In mice subjected to hindlimb
suspension, the expression of several cytoskeleton proteins
was modified in the atrophying muscles.64 A remodelling of
the cytoskeleton appears essential for allowing the degrada-
tion of filamentous proteins and for preserving the functional
integrity of myofibrils during muscle atrophy.67 Similarly, sev-
eral proteins involved in muscle architecture and muscle con-
traction were either down-regulated or up-regulated in both
LC and HD patients (Table 2). Indeed, a group of proteins
whose expression levels were modified in the muscle of LC
and HD patients belong to the cytoskeleton organization in-
cluding intermediate filaments. We found an up-regulation
of ARPC1A (component of the ARP2/3 complex), cofilin 2
(CFL2), and profilin 2 (PFN2) (regulators of actin
polymerization/depolymerization) and a down-regulation of
filamin A (FLNA) (a cellular actin-network stabilizer) and junc-
tion plakoglobin (JUP) (a mechanical stress transduction pro-
tein). We have also noted increased levels of myopalladin
(MYPN), a protein that participates to thin filament assembly
by linking nebulin and α-actinin.68 Its translocation into the
cytosol may witness the destabilization of the sarcomeric
structure and the subsequent degradation of sarcomeric pro-
teins by the UPS. Furthermore, profound modifications of ex-
tracellular matrix components were observed between
control and diseased patients (Table 2) like peptidase D
(PEPD) (+15 to +40%, P < 1.0E02), a protein involved in col-
lagen synthesis, and the acireductone dioxygenase 1(ADI1),
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an extracellular protease inhibitor (39 to 61%,
P < 1.0E04), which further suggest a profibrotic process
in skeletal muscles from LC and HD patients. Regarding mus-
cle adiposity, we found an increase in fat tissue obesity gene
expression (+14 to +40%, P< 1.0E02). Fat tissue obesity is a
nucleic acid demethylase that controls the expression of
genes involved in energy metabolism. Its overexpression has
been shown to cause intracellular lipid accumulation in skele-
tal muscle cells69 and increased white adipose tissue.70 Inter-
estingly, proteome analysis also revealed an activation of the
Wnt/β-catenin pathway in both groups, which is known to
have a dual function as it is involved either in muscle regen-
eration71 or in fibrosis.72 Inhibition of canonical Wnt signalling
in aged skeletal muscle has the potential to reduce fibrosis
development.72 This suggests that targeting the canonical
Wnt pathway may be a potential approach for preserving
muscle integrity.
The discovery of >230 proteins differentially expressed in
the HD and LC patients has several implications. First, it
means that profound modifications of skeletal muscle metab-
olism occur and that they persist throughout the course of
the pathology. Thus, the identified markers are potentially in-
teresting not only for characterizing muscle atrophy but also
for better understanding the atrophy process. The second
point is that these markers were not equally modified; that
is, some of them reached a five-fold to seven-fold increase
while others were ‘only’ increased by 50%. This does not
mean the higher the better. Future studies will have to iden-
tify the most reliable markers, that is, the ones systematically
altered in most if not all patients and predictive of muscle
mass loss when using larger cohorts. The third important im-
plication is that these muscle markers will be hardly useful for
direct clinical use (muscle biopsies). We are currently working
on the detection of blood markers that could reflect the
atrophying programme observed in skeletal muscle, this
study being an obligatory and highly valuable step.
Conclusions
We observed an activation of the UPS and autophagy proteo-
lytic systems and common proteomic modifications in
atrophying skeletal muscles from LC and HD patients. Our
data suggest that the degradation of the contractile appara-
tus and of the muscular cell structure (cytoskeleton) may be
highly similar whatever the pathology, which means similar
therapeutic strategies may be applied for preserving muscle
mass. Our work represents a proof of concept with a limited
number of patients, and future work will have to confirm
these data on a larger number of patients with similar or dif-
ferent pathologies. Another important issue will be to deter-
mine whether the muscle-atrophying programme may also
induce common variations in blood (e.g. at the transcriptomic
level), a more easy-to-handle compartment in patients. If so,
this may end up with a valuable diagnostic tool for early de-
tection of catabolic situations or for following disease
remission.
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